Literature DB >> 6248221

Comparative pharmacokinetics of cefoperazone and cefotaxime.

H Lode, B Kemmerich, P Koeppe, D Belmega, H Jendroschek.   

Abstract

The pharmacokinetics of cefoperazone and cefotaxime were compared in a crossover, randomized study in ten healthy volunteers (5 males, 5 females). Each subject received 2.0 gm of the study drug administered by an IV infusion over 30 minutes. Serum concentrations of cefoperazone and cefotaxime at the end of the infusion (zero time) were 254 mg/liter and 144 mg/liter, respectively. Comparative results at other times were the following: four hours, 20 mg/liter and 3 mg/liter; eight hours, 4.4 mg/liter and 0.3 mg/liter; and 12 hours, 1.2 mg/liter and 0.0 mg/liter. Twenty-one percent of the 2.0-gm single dose of cefoperazone was recovered in the urine during the first 24 hours following dosing, compared to 52% for cefotaxime. The renal clearance of cefoperazone was also determined in three patients during four hours. The results of the investigations will be discussed in view of the clinical relevance.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6248221

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  15 in total

1.  Multiple-dose pharmacokinetics and toleration of intravenously administered cefoperazone and sulbactam when given as single agents or in combination.

Authors:  D P Reitberg; T J Whall; M Chung; D Blickens; H Swarz; J Arnold
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

2.  Antimicrobial activity of ceftriaxone, cefotaxime, desacetylcefotaxime, and cefotaxime-desacetylcefotaxime in the presence of human serum.

Authors:  R N Jones; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191

3.  Comparative pharmacokinetics of cefoperazone and cefamandole.

Authors:  S Srinivasan; E L Francke; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

4.  Pharmacokinetics of ceftriaxone following intravenous administration of a 3 g dose.

Authors:  P J McNamara; K Stoeckel; W H Ziegler
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

5.  Comparative pharmacokinetics of cefoperazone, cefotaxime, and moxalactam.

Authors:  B Kemmerich; H Lode; G Belmega; T Jendroschek; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1983-03       Impact factor: 5.191

Review 6.  The third generation cephalosporins.

Authors:  B Farber; R C Moellering
Journal:  Bull N Y Acad Med       Date:  1982-11

7.  Pharmacokinetics of cefoperazone (2.0 g) and sulbactam (1.0 g) coadministered to subjects with normal renal function, patients with decreased renal function, and patients with end-stage renal disease on hemodialysis.

Authors:  D P Reitberg; D A Marble; R W Schultz; T J Whall; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

8.  Pharmacokinetics of ceftriaxone in humans.

Authors:  I H Patel; S Chen; M Parsonnet; M R Hackman; M A Brooks; J Konikoff; S A Kaplan
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

Review 9.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

Review 10.  Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-03       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.